explore -WSS

explore

author：comprehensive 2025-10-01 00:45:44 - browse：97

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

WSS

South Korea throws huge K

Digital health: a case of mistaken identity

Liver decline slowed by off

FDA panel issues narrow recommendation for Covid vaccine booster doses

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

entertainment

explore

explore

Supreme Court strikes down use of affirmative action

For longer

The high cost of giving birth even with insurance

Wegovy trial has doctors encouraged over new possibilities

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Digital health: a case of mistaken identity

Novavax promises a turnaround & Lilly roils the obesity market

Wegovy trial has doctors encouraged over new possibilities

Wikipedia

American woman, child freed after being kidnapped in Haiti last month

FDA panel issues narrow recommendation for Covid vaccine booster doses

Naloxone nonprofit donates 200,000 doses after FDA approval

ASCO eve: Let’s set the table for this year's meeting

Listen: More tumult at BIO & coercive care for sickle cell patients

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

explore

leisure time

Wikipedia

knowledge